Although the effects of proteasome inhibition are highly pleiotropic, the finding that bortezomib treatment leads to a rapid and parallel decrease in both SMC3 and ESR1 gene expression opens an interesting new possible mechanism for its potential utility in the treatment of ERα-positive breast cancer. Here, SMC3 is linked to breast carcinoma.